Sleiman, J., A. Charabaty, and A. ur Rahman. “Do Pharmacokinetics Justify Dose-Optimization for Loss of Response to Vedolizumab in IBD?”. @Gijournal, vol. 1, no. 1, Aug. 2021, doi:10.52697/gijournal.v1i1.23.